Weekly multidisciplinary coordination meetings (RCP) have been held at Institute Curie since October 2014.
Feedback on 1 year of experience
In an article published in 2016, Pincez et al went over to the results observed following the adaptation of molecular RCP to a pediatric context.
In one year, 60 children and young adults benefitted from this new process. Molecular alterations were identified in 23 patients and 26% of them were able to receive a targeted treatment for the genomic alteration.
While the principal limitation is still the lack of targeted therapies to address all identified abnormalities, this article clearly demonstrates the feasibility and value of this new therapeutic approach for young patients.
The establishment of a high-throughput sequencing platform at Institut Curie and the development of the SHIVA clinical trial, funded in part by SIRIC were decisive assets for the deployment of molecular RCPs as early as 2014.